Mallinckrodt Hospital Products IP Limited

Mallinckrodt Pharmaceuticals Ireland Limited

General Electric Company

Ino Therapeutics Gmbh

Mallinckrodt Pharmactuticals Ireland Limited

Mallinckrodt Hospital Products IP Unlimited Company

Jaron Matthew Acker

Craig R Tolmie

Jeff Milsap

Jeffrey Schmidt

Robin Roehl

Thomas Kohlmann

Robert Q Tham

Jim Potenziano

Curtis B Irwin

Craig Flanagan

John R Pinkert

Joseph J Medicis

Robert Schnitman

Sarah Jayne Ridley

Kenneth Lee Soliva

John Klaus

Andreas Tzanetakis

John Falligant

Kristopher Bilek

Daniel Juhyung Lee

Nicholas S Reback

Frank Kenneth Schweighardt

David William Newman

Andrew Levi

Gary Choncholas

Douglas Alan Greene

Brian McCormack

Michael McAtamney

Caeli B D Rice

David Robert Strait

Curtis Benjamin Irwin

Jarod Beukelman

Muhammad Asif

Lien-Lung Sheu

Andreas Tzanet Akis

Cedric Assambo

Peter James Clark

Robert Quin Yew Tham

Tom Kohlmann

Paul R Micheli

Jennifer L Pakter

Craig Rus Tolmie

Michael Mcatamney

David Newman

Gary J Choncholas

Kristopher John Bilek

The present disclosure generally relates to systems and methods for delivery of therapeutic gas to patients, using techniques to compensate for disruptions in breathing gas flow measurement, such as when breathing gas flow measurement is unavailable or unreliable. Such techniques include using historical breathing gas flow rate data, such as moving average flow rates, moving median flow rates and/or flow waveforms. At least some of these techniques can be used to ensure that interruption in therapeutic gas delivery is minimized or eliminated.

Compensating for disruptions in breathing gas flow measurement

Therapy gas delivery systems that provide run-time-to-empty information to a user of the system and methods for administering therapeutic gas to a patient. The therapeutic gas delivery system may include a gas pressure sensor attachable to a therapeutic gas source that communicates therapeutic gas pressure data to a therapeutic gas delivery system controller, a gas temperature sensor positioned to measure gas temperature in the therapeutic gas source that communicates therapeutic gas temperature data to the therapeutic gas delivery system controller, at least one flow controller that communicates therapeutic gas flow rate data to the therapeutic gas delivery system controller, at least one flow sensor that communicates flow rate data to the therapeutic gas delivery system controller, and at least one display that communicates run-time-to-empty to a user of the therapeutic gas delivery system. The therapeutic gas delivery system controller of the system includes a processor that executes an algorithm to calculate the run-time-to-empty from the data received from the gas pressure sensor, temperature sensor, flow controller and flow sensor, and directs the result to the display.

Intelligent gas source management

Injector module

Display screen or portion thereof with graphical user interface

Therapeutic gas delivery cart

A removable gas sensor module is provided for a therapeutic gas delivery device. The gas sensor module includes a sample chamber which receives a sample gas from the therapeutic gas delivery device. A gas detection unit includes a plurality of sensors operable to measure at least one property of the sample gas. The sensors include two or more of a gas detection sensor, a humidity sensor, a temperature sensor, or a combination thereof. The gas sensor module is self-contained within the therapeutic gas delivery device and swappable with another gas sensor module.

Gas sensor module

The principles and embodiments of the present invention relate to methods and systems for safely providing NO to a recipient for inhalation therapy. There are many potential safety issues that may arise from using a reactor cartridge that converts NOto NO, including exhaustion of consumable reactants of the cartridge reactor. Accordingly, various embodiments of the present invention provide systems and methods of determining the remaining useful life of a NO-to-NO reactor cartridge and/or a breakthrough of NO, and providing an indication of the remaining useful life and/or breakthrough.

Systems and methods for manufacturing and safety of an NO-to-NO reactor cartridge used to deliver no for inhalation therapy to a patient

Systems and methods for delivery of therapeutic gas

Described is an apparatus for monitoring nitric oxide delivery, wherein such apparatus comprises a display that provides a visual and/or numeric indication of the calculated dose of nitric oxide. Also described is a method of monitoring nitric oxide delivery, wherein the breathing gas flow rate and therapeutic gas flow rate are measured and used to determine the calculated dose of nitric oxide, which is then displayed. In some embodiments, an alert is provided when the calculated dose rises above or falls below a predetermined level or range.

Apparatus and method for monitoring nitric oxide delivery

Enhanced performance verification port for therapeutic gas delivery

The present invention provides clinical decision support that can be used with non-portable and portable systems when delivering and/or monitoring delivery of a therapeutic gas comprising nitric oxide to a patient. Further, clinical decision support can be used with non-portable and portable systems during delivery and/or monitoring of delivery of therapeutic gas when nebulized drugs may and/or may not be being delivered to a patient (e.g., when nebulizers are delivered upstream in the inspiratory limb of the breathing circuit, into a breathing gas delivery system, etc.).

Clinical decision support system and methods

Growing community of inventors

Madison, WI, United States of America

Jaron Matthew Acker